Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Clinical genitourinary cancer·2026

Same author

Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review.

European journal of human genetics : EJHG·2026

Same author

Response to Yu, Wang and Ge.

Journal of the National Cancer Institute·2026

Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026

Same author

Prognostic relevance and molecular correlates of Claudin-1 expression in pancreatic neuroendocrine tumors.

Human pathology·2026

Same author

Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype.

European journal of cancer (Oxford, England : 1990)·2026

Search research articles

Related Experiment Video

Updated: May 1, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Pertuzumab: development beyond breast cancer.

Philippe Barthélémy¹, Julie Leblanc, Veronica Goldbarg

¹Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg, 1 Place de l'hôpital, 67091 Strasbourg, France. j-emmanuel.kurtz@chru-strasbourg.fr.

Anticancer Research

|April 3, 2014

Summary

Pertuzumab is a novel dimerization inhibitor approved for HER2-positive breast cancer. This review explores its efficacy and biological rationale in other solid tumors beyond breast cancer.

Keywords:

NSCLC Pertuzumab colorectal cancer gastric cancer ovarian cancer prostate cancer review solid tumors

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Experiment Videos

Last Updated: May 1, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Area of Science:

Oncology
Immunotherapy
Molecular Biology

Background:

Pertuzumab is a first-in-class monoclonal antibody targeting Human Epidermal growth factor Receptor 2 (HER2) dimerization.
It is approved for HER2-positive breast cancer in metastatic and neoadjuvant settings, improving survival and response rates when combined with trastuzumab and docetaxel.

Purpose of the Study:

To review the biological rationale, preclinical, and clinical evidence for pertuzumab in solid tumors other than breast cancer.
To summarize ongoing clinical trials investigating pertuzumab in diverse solid tumor types.

Main Methods:

Review of published preclinical studies evaluating pertuzumab's mechanism of action and efficacy.
Analysis of clinical trial data (Phase I, II, and III) assessing pertuzumab in various solid tumors.
Synthesis of information on ongoing research and clinical development.

Main Results:

Pertuzumab demonstrates a strong biological rationale for targeting HER2-expressing solid tumors.
Early clinical data suggests potential activity in certain non-breast solid tumors, though further investigation is required.
Ongoing trials are actively exploring its efficacy and safety in combination therapies.

Conclusions:

Pertuzumab's development extends beyond breast cancer, with potential applications in other HER2-positive solid tumors.
Further research and clinical trials are crucial to establish its role in treating a broader range of cancers.